Testing a new injection to treat active lupus

This is an early-stage clinical trial testing JY231, an experimental injectable medication for people with active systemic lupus erythematosus (SLE) that hasn't been adequately controlled by standard treatments. The study will enroll approximately 10–20 patients to evaluate whether this medication is safe and whether it helps reduce lupus activity. Researchers will carefully monitor you for side effects and measure how well the treatment works.

Lupus is a serious autoimmune disease where the body attacks its own tissues, causing inflammation and damage. While current treatments help many people, some patients—like those in this trial—continue to experience active disease despite being on multiple medications. This trial is testing whether the new treatment could be a helpful option for people whose lupus remains uncontrolled.